Observation of the Effect and Mechanism of Multi Tunnel Minimally Invasive Treatment for Xanthelasma Palpebrarum

Launched by FUZHOU FIRST GENERAL HOSPITAL SKIN DISEASE PREVENTION AND CONTROL HOSPITAL · Mar 5, 2025

Keywords

ClinConnect Summary

This study, taking place at Fuzhou First General Hospital in China, is testing new ways to treat xanthelasma palpebrarum (yellow cholesterol deposits near the eyelids). Researchers compare three approaches: (1) injecting heparin around the lesion, (2) a special multi-level, multi-tunnel puncture treatment, and (3) the combination of both methods. People will be randomly assigned to one of these three groups, and the main goal is to see how much the treated area shrinks by 12 weeks after starting treatment. About 270 adults are planned to enroll, with the study starting in early 2025 and expected to finish around 2029.

Who can join? Adults aged 18 to 65 with a clinical diagnosis of xanthelasma palpebrarum who can safely receive heparin injections and the puncture treatment. Exclusions include bleeding problems (like hemophilia) or certain heart or brain conditions. If you’re eligible and choose to participate, you can expect multiple treatment sessions over roughly 12 weeks, spaced about every 5 to 14 days depending on the group. The study has ethics approval and supervision, with safety monitoring and privacy protections in place.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinical diagnosis of xanthelasma palpebrarum
• • Must be able to receive heparin sodium injection and multi tunnel minimally invasive treatment
• Exclusion Criteria:
• • Hemophilia
• • Coronary heart disease
• • Myocardial infarction
• • Cerebral infarction